Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedUpdated the site revision from v3.4.1 to v3.4.2; no user-facing content or functionality appears to be affected.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, which appears to be a minor backend/system update with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedGlossary visibility controls were added (Show glossary, Hide glossary) and footer metadata was updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check40 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 in the page footer.SummaryDifference0.1%

- Check69 days agoChange DetectedFooter now displays Revision: v3.3.3; the HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 reference were removed.SummaryDifference0.1%

- Check91 days agoChange DetectedPublications section text was updated to clarify auto-fill from PubMed, and the revision/version numbers were updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.